Description

Retatrutide is an investigational once‑weekly product that activates three metabolic hormone receptors (GLP‑1, GIP, and glucagon) to support research into weight‑related metabolic pathways. It is not FDA‑approved, not available for purchase, and is currently being evaluated in Phase 3 clinical trials. Clinics may reference its research status and mechanism of action, but cannot make efficacy claims or imply approval.